CapsoVision initiated with a Buy at Roth Capital

Roth Capital analyst Jason Wittes initiated coverage of CapsoVision (CV) with a Buy rating and $6 price target The firm believes the company is progressing advanced imaging and artificial intelligence implementation with its capsule endoscopy platform for gastrointestinal screening and diagnosis. CapsoVision is positioned for 19.5% growth in 2025 with its initial small bowel indication, and also recently submitted 510(k) approval for the much larger colon indication, the analyst tells investors in a research note. It sees this boosting revenue growth in 2026.